Form 4: Cytokinetics Director Acquires Shares Through Stock Retainer Program

Edward M. Kaye, a director at Cytokinetics Inc, acquired 324 shares of common stock through the Director Stock in lieu of Cash Retainer Program on April 15, 2025.

Summary

• On April 15, 2025, Edward M. Kaye, a director of Cytokinetics Inc., acquired 324 shares of the company's common stock.
• The acquisition was made through the Director Stock in lieu of Cash Retainer Program.
• The price per share was $38.56.
• Following the transaction, Dr. Kaye directly owns 25,961 shares of Cytokinetics Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction related to director compensation. The director's participation in the stock retainer program could be seen as a slightly positive signal.

Positives

• The director's participation in the stock retainer program demonstrates confidence in the company's future.

Industry Context

Directors receiving stock in lieu of cash compensation is a fairly common practice, especially in biotech companies, as it aligns their interests with those of shareholders and conserves cash.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with theirs.

Key Dates

Keywords

Cytokinetics, Director, Stock acquisition, Form 4, Insider trading, Edward M. Kaye, Stock Retainer Program